Author

Young Liu

Institution: Denovo Biopharma LLC (United States)

Observed institution: Denovo Biopharma LLC (United States)

OpenAlex ID: A5032067232

ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1

2020 · Grzegorz S Nowakowski, Jun Zhu, et al. · Future Oncology · 22

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

2019 · Jun Zhu, Grzegorz Nowakowski, et al. · Blood · 1

ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1.

2019 · Stephen Smith, Jun Zhu, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 23

H-index: 1

I10-index: 1